spike glycoprotein Search Results


94
Native Antigen Inc s full length
S Full Length, supplied by Native Antigen Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spike+glycoprotein/SARS-CoV-2+Spike+Glycoprotein+(Full-Length)%2C+His-Tag+(CHO)/pmc12058664-87-13-45
Average 94 stars, based on 1 article reviews
s full length - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
Cusabio partial human novel coronavirus spike glycoprotein
Partial Human Novel Coronavirus Spike Glycoprotein, supplied by Cusabio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spike+glycoprotein/Recombinant+Human+Novel+Coronavirus+Spike+glycoprotein(S)%2C+partial/pm36057099-121-12-21
Average 90 stars, based on 1 article reviews
partial human novel coronavirus spike glycoprotein - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

92
Cusabio recombinant human novel coronavirus spike glycoprotein
Recombinant Human Novel Coronavirus Spike Glycoprotein, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spike+glycoprotein/Recombinant+Human+Novel+Coronavirus+Spike+glycoprotein(S)%2Cpartial/10__3390_slash_surfaces8040079-78-7-25
Average 92 stars, based on 1 article reviews
recombinant human novel coronavirus spike glycoprotein - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

96
ProSci Incorporated anti sars cov 2 spike rbd protein
Anti Sars Cov 2 Spike Rbd Protein, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spike+glycoprotein/SARS-CoV-2+(COVID-19)+Spike+RBD+Antibody/bio_rxiv__2020__08__14__251207-266-17-21
Average 96 stars, based on 1 article reviews
anti sars cov 2 spike rbd protein - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

88
MedChemExpress sars cov list
COVID19-specific collections and chemical libraries
Sars Cov List, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spike+glycoprotein/SARS-CoV+S/pmc07778969-15-2-9
Average 88 stars, based on 1 article reviews
sars cov list - by Bioz Stars, 2026-11
88/100 stars
  Buy from Supplier

92
Native Antigen Inc sars coronavirus spike glycoprotein s2
Workflow and timeline for <t>SARS-CoV-2</t> neutralizing antibodies identification The overall scheme shows three different phases for the identification of SARS-CoV-2 neutralizing antibodies (nAbs). Phase 1 consisted in the enrolment of COVID-19 patients (n = 14) from which PBMCs were isolated. Memory B cells were single-cell sorted (n = 4,277), and after 2 weeks of incubation, antibodies were screened for their binding specificity against the S protein trimer and <t>S1/S2</t> domains. Once S protein-specific monoclonal antibodies (mAbs) were identified (n = 1,731) phase 2 started. All specific mAbs were tested in vitro to evaluate their neutralization activity against the authentic SARS-CoV-2 virus, and 453 nAbs were identified. nAbs showing different binding profiles on the S protein surface were selected for further functional characterization and to identify different neutralizing regions on the antigen. Phase 3 starts with the characterization of the heavy and light chain sequences of selected mAbs (n = 14) and the engineering of the Fc portion of three most promising candidates. The latter were also selected for structural analyses that allowed the identification of the neutralizing epitopes on the S protein. Finally, the most potent antibody was tested for its prophylactic and therapeutic effect in a golden Syrian hamster model of SARS-CoV-2 infection.
Sars Coronavirus Spike Glycoprotein S2, supplied by Native Antigen Inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spike+glycoprotein/SARS-CoV-2+Spike+Glycoprotein+(S2)%2C+Sheep+Fc-Tag+(HEK293)/pmc07901298-63-0-6
Average 92 stars, based on 1 article reviews
sars coronavirus spike glycoprotein s2 - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

93
Native Antigen Inc rbd
Workflow and timeline for <t>SARS-CoV-2</t> neutralizing antibodies identification The overall scheme shows three different phases for the identification of SARS-CoV-2 neutralizing antibodies (nAbs). Phase 1 consisted in the enrolment of COVID-19 patients (n = 14) from which PBMCs were isolated. Memory B cells were single-cell sorted (n = 4,277), and after 2 weeks of incubation, antibodies were screened for their binding specificity against the S protein trimer and <t>S1/S2</t> domains. Once S protein-specific monoclonal antibodies (mAbs) were identified (n = 1,731) phase 2 started. All specific mAbs were tested in vitro to evaluate their neutralization activity against the authentic SARS-CoV-2 virus, and 453 nAbs were identified. nAbs showing different binding profiles on the S protein surface were selected for further functional characterization and to identify different neutralizing regions on the antigen. Phase 3 starts with the characterization of the heavy and light chain sequences of selected mAbs (n = 14) and the engineering of the Fc portion of three most promising candidates. The latter were also selected for structural analyses that allowed the identification of the neutralizing epitopes on the S protein. Finally, the most potent antibody was tested for its prophylactic and therapeutic effect in a golden Syrian hamster model of SARS-CoV-2 infection.
Rbd, supplied by Native Antigen Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spike+glycoprotein/SARS-CoV-2+Spike+Glycoprotein+(S1)+RBD%2C+His-Tag+(HEK293)/pm36367941-352-14-18
Average 93 stars, based on 1 article reviews
rbd - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Native Antigen Inc rec31806 100 sars cov 2 spike glycoprotein s1
Workflow and timeline for <t>SARS-CoV-2</t> neutralizing antibodies identification The overall scheme shows three different phases for the identification of SARS-CoV-2 neutralizing antibodies (nAbs). Phase 1 consisted in the enrolment of COVID-19 patients (n = 14) from which PBMCs were isolated. Memory B cells were single-cell sorted (n = 4,277), and after 2 weeks of incubation, antibodies were screened for their binding specificity against the S protein trimer and <t>S1/S2</t> domains. Once S protein-specific monoclonal antibodies (mAbs) were identified (n = 1,731) phase 2 started. All specific mAbs were tested in vitro to evaluate their neutralization activity against the authentic SARS-CoV-2 virus, and 453 nAbs were identified. nAbs showing different binding profiles on the S protein surface were selected for further functional characterization and to identify different neutralizing regions on the antigen. Phase 3 starts with the characterization of the heavy and light chain sequences of selected mAbs (n = 14) and the engineering of the Fc portion of three most promising candidates. The latter were also selected for structural analyses that allowed the identification of the neutralizing epitopes on the S protein. Finally, the most potent antibody was tested for its prophylactic and therapeutic effect in a golden Syrian hamster model of SARS-CoV-2 infection.
Rec31806 100 Sars Cov 2 Spike Glycoprotein S1, supplied by Native Antigen Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spike+glycoprotein/SARS-CoV-2+Spike+Glycoprotein+(S1)%2C+Sheep+Fc-Tag+(HEK293)/pmc07953841-77-22-55
Average 93 stars, based on 1 article reviews
rec31806 100 sars cov 2 spike glycoprotein s1 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
Cusabio s rbd
Workflow and timeline for <t>SARS-CoV-2</t> neutralizing antibodies identification The overall scheme shows three different phases for the identification of SARS-CoV-2 neutralizing antibodies (nAbs). Phase 1 consisted in the enrolment of COVID-19 patients (n = 14) from which PBMCs were isolated. Memory B cells were single-cell sorted (n = 4,277), and after 2 weeks of incubation, antibodies were screened for their binding specificity against the S protein trimer and <t>S1/S2</t> domains. Once S protein-specific monoclonal antibodies (mAbs) were identified (n = 1,731) phase 2 started. All specific mAbs were tested in vitro to evaluate their neutralization activity against the authentic SARS-CoV-2 virus, and 453 nAbs were identified. nAbs showing different binding profiles on the S protein surface were selected for further functional characterization and to identify different neutralizing regions on the antigen. Phase 3 starts with the characterization of the heavy and light chain sequences of selected mAbs (n = 14) and the engineering of the Fc portion of three most promising candidates. The latter were also selected for structural analyses that allowed the identification of the neutralizing epitopes on the S protein. Finally, the most potent antibody was tested for its prophylactic and therapeutic effect in a golden Syrian hamster model of SARS-CoV-2 infection.
S Rbd, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spike+glycoprotein/Recombinant+Human+Novel+Coronavirus+Spike+glycoprotein(S)%2Cpartial/pm34233324-53-1-2
Average 93 stars, based on 1 article reviews
s rbd - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

93
ProSci Incorporated room temperature with anti s s1
Workflow and timeline for <t>SARS-CoV-2</t> neutralizing antibodies identification The overall scheme shows three different phases for the identification of SARS-CoV-2 neutralizing antibodies (nAbs). Phase 1 consisted in the enrolment of COVID-19 patients (n = 14) from which PBMCs were isolated. Memory B cells were single-cell sorted (n = 4,277), and after 2 weeks of incubation, antibodies were screened for their binding specificity against the S protein trimer and <t>S1/S2</t> domains. Once S protein-specific monoclonal antibodies (mAbs) were identified (n = 1,731) phase 2 started. All specific mAbs were tested in vitro to evaluate their neutralization activity against the authentic SARS-CoV-2 virus, and 453 nAbs were identified. nAbs showing different binding profiles on the S protein surface were selected for further functional characterization and to identify different neutralizing regions on the antigen. Phase 3 starts with the characterization of the heavy and light chain sequences of selected mAbs (n = 14) and the engineering of the Fc portion of three most promising candidates. The latter were also selected for structural analyses that allowed the identification of the neutralizing epitopes on the S protein. Finally, the most potent antibody was tested for its prophylactic and therapeutic effect in a golden Syrian hamster model of SARS-CoV-2 infection.
Room Temperature With Anti S S1, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spike+glycoprotein/SARS-CoV-2+(COVID-19)+Spike+S1+Antibody/pmc10447459-81-31-36
Average 93 stars, based on 1 article reviews
room temperature with anti s s1 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

90
ProSci Incorporated sars cov 2 spike rabbit polyclonal antibody
Workflow and timeline for <t>SARS-CoV-2</t> neutralizing antibodies identification The overall scheme shows three different phases for the identification of SARS-CoV-2 neutralizing antibodies (nAbs). Phase 1 consisted in the enrolment of COVID-19 patients (n = 14) from which PBMCs were isolated. Memory B cells were single-cell sorted (n = 4,277), and after 2 weeks of incubation, antibodies were screened for their binding specificity against the S protein trimer and <t>S1/S2</t> domains. Once S protein-specific monoclonal antibodies (mAbs) were identified (n = 1,731) phase 2 started. All specific mAbs were tested in vitro to evaluate their neutralization activity against the authentic SARS-CoV-2 virus, and 453 nAbs were identified. nAbs showing different binding profiles on the S protein surface were selected for further functional characterization and to identify different neutralizing regions on the antigen. Phase 3 starts with the characterization of the heavy and light chain sequences of selected mAbs (n = 14) and the engineering of the Fc portion of three most promising candidates. The latter were also selected for structural analyses that allowed the identification of the neutralizing epitopes on the S protein. Finally, the most potent antibody was tested for its prophylactic and therapeutic effect in a golden Syrian hamster model of SARS-CoV-2 infection.
Sars Cov 2 Spike Rabbit Polyclonal Antibody, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spike+glycoprotein/SARS-CoV-2+(COVID-19)+S1%2BS2+ECD+(S-ECD)+Recombinant+Protein/pmc07935909-266-14-20
Average 90 stars, based on 1 article reviews
sars cov 2 spike rabbit polyclonal antibody - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

88
ProSci Incorporated sars spike protein antibody
Workflow and timeline for <t>SARS-CoV-2</t> neutralizing antibodies identification The overall scheme shows three different phases for the identification of SARS-CoV-2 neutralizing antibodies (nAbs). Phase 1 consisted in the enrolment of COVID-19 patients (n = 14) from which PBMCs were isolated. Memory B cells were single-cell sorted (n = 4,277), and after 2 weeks of incubation, antibodies were screened for their binding specificity against the S protein trimer and <t>S1/S2</t> domains. Once S protein-specific monoclonal antibodies (mAbs) were identified (n = 1,731) phase 2 started. All specific mAbs were tested in vitro to evaluate their neutralization activity against the authentic SARS-CoV-2 virus, and 453 nAbs were identified. nAbs showing different binding profiles on the S protein surface were selected for further functional characterization and to identify different neutralizing regions on the antigen. Phase 3 starts with the characterization of the heavy and light chain sequences of selected mAbs (n = 14) and the engineering of the Fc portion of three most promising candidates. The latter were also selected for structural analyses that allowed the identification of the neutralizing epitopes on the S protein. Finally, the most potent antibody was tested for its prophylactic and therapeutic effect in a golden Syrian hamster model of SARS-CoV-2 infection.
Sars Spike Protein Antibody, supplied by ProSci Incorporated, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spike+glycoprotein/SARS+Spike+Antibody/ppr0265972-92-24-57
Average 88 stars, based on 1 article reviews
sars spike protein antibody - by Bioz Stars, 2026-11
88/100 stars
  Buy from Supplier

Image Search Results


COVID19-specific collections and chemical libraries

Journal: Nucleic Acids Research

Article Title: COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics

doi: 10.1093/nar/gkaa969

Figure Lengend Snippet: COVID19-specific collections and chemical libraries

Article Snippet: MedChemExpress , SARS-CoV List of Drugs , 76 , https://www.medchemexpress.com/Targets/SARS-CoV.html.

Techniques: Protein-Protein interactions, Drug discovery

Workflow and timeline for SARS-CoV-2 neutralizing antibodies identification The overall scheme shows three different phases for the identification of SARS-CoV-2 neutralizing antibodies (nAbs). Phase 1 consisted in the enrolment of COVID-19 patients (n = 14) from which PBMCs were isolated. Memory B cells were single-cell sorted (n = 4,277), and after 2 weeks of incubation, antibodies were screened for their binding specificity against the S protein trimer and S1/S2 domains. Once S protein-specific monoclonal antibodies (mAbs) were identified (n = 1,731) phase 2 started. All specific mAbs were tested in vitro to evaluate their neutralization activity against the authentic SARS-CoV-2 virus, and 453 nAbs were identified. nAbs showing different binding profiles on the S protein surface were selected for further functional characterization and to identify different neutralizing regions on the antigen. Phase 3 starts with the characterization of the heavy and light chain sequences of selected mAbs (n = 14) and the engineering of the Fc portion of three most promising candidates. The latter were also selected for structural analyses that allowed the identification of the neutralizing epitopes on the S protein. Finally, the most potent antibody was tested for its prophylactic and therapeutic effect in a golden Syrian hamster model of SARS-CoV-2 infection.

Journal: Cell

Article Title: Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

doi: 10.1016/j.cell.2021.02.035

Figure Lengend Snippet: Workflow and timeline for SARS-CoV-2 neutralizing antibodies identification The overall scheme shows three different phases for the identification of SARS-CoV-2 neutralizing antibodies (nAbs). Phase 1 consisted in the enrolment of COVID-19 patients (n = 14) from which PBMCs were isolated. Memory B cells were single-cell sorted (n = 4,277), and after 2 weeks of incubation, antibodies were screened for their binding specificity against the S protein trimer and S1/S2 domains. Once S protein-specific monoclonal antibodies (mAbs) were identified (n = 1,731) phase 2 started. All specific mAbs were tested in vitro to evaluate their neutralization activity against the authentic SARS-CoV-2 virus, and 453 nAbs were identified. nAbs showing different binding profiles on the S protein surface were selected for further functional characterization and to identify different neutralizing regions on the antigen. Phase 3 starts with the characterization of the heavy and light chain sequences of selected mAbs (n = 14) and the engineering of the Fc portion of three most promising candidates. The latter were also selected for structural analyses that allowed the identification of the neutralizing epitopes on the S protein. Finally, the most potent antibody was tested for its prophylactic and therapeutic effect in a golden Syrian hamster model of SARS-CoV-2 infection.

Article Snippet: SARS Coronavirus Spike Glycoprotein (S2) , The Native Antigen Company , Cat#REC31807.

Techniques: Isolation, Incubation, Binding Assay, In Vitro, Neutralization, Activity Assay, Virus, Functional Assay, Infection

Gating strategy for single-cell sorting and monoclonal antibodies screening for S protein S1 + S2 subunits binding and neutralization of binding (NoB) activity, related to <xref ref-type=Figure 2 (A) Starting from top left to the right panel, the gating strategy shows: Live/Dead; Morphology; CD19 + B cells; CD19 + CD27 + IgD - ; CD19 + CD27 + IgD - IgM - ; CD19 + CD27 + IgD - IgM - S-protein + B cells. (B) The graph shows supernatants tested for binding to the SARS-CoV-2 S-protein S1 + S2 subunits. Threshold of positivity has been set as two times the value of the blank (dotted line). Darker dots represent mAbs which bind to the S1 + S2 while light yellow dots represent mAbs which do not bind. (B) The graph shows supernatants tested by NoB assay. Threshold of positivity has been set as 50% of binding neutralization (dotted line). Dark blue dots represent mAbs able to neutralize the binding between SARS-CoV-2 and receptors on Vero E6 cells, while light blue dots represent non-neutralizing mAbs. " width="100%" height="100%">

Journal: Cell

Article Title: Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

doi: 10.1016/j.cell.2021.02.035

Figure Lengend Snippet: Gating strategy for single-cell sorting and monoclonal antibodies screening for S protein S1 + S2 subunits binding and neutralization of binding (NoB) activity, related to Figure 2 (A) Starting from top left to the right panel, the gating strategy shows: Live/Dead; Morphology; CD19 + B cells; CD19 + CD27 + IgD - ; CD19 + CD27 + IgD - IgM - ; CD19 + CD27 + IgD - IgM - S-protein + B cells. (B) The graph shows supernatants tested for binding to the SARS-CoV-2 S-protein S1 + S2 subunits. Threshold of positivity has been set as two times the value of the blank (dotted line). Darker dots represent mAbs which bind to the S1 + S2 while light yellow dots represent mAbs which do not bind. (B) The graph shows supernatants tested by NoB assay. Threshold of positivity has been set as 50% of binding neutralization (dotted line). Dark blue dots represent mAbs able to neutralize the binding between SARS-CoV-2 and receptors on Vero E6 cells, while light blue dots represent non-neutralizing mAbs.

Article Snippet: SARS Coronavirus Spike Glycoprotein (S2) , The Native Antigen Company , Cat#REC31807.

Techniques: FACS, Binding Assay, Neutralization, Activity Assay

Characterization and distribution of SARS-CoV-2 S protein-specific nAbs, related to <xref ref-type=Figure 2 (A) The bar graph shows the distribution of nAbs binding to different S-protein domains. In dark red, light blue and gray are shown antibodies binding to the S1-domain, S2-domain and S-protein trimer respectively. The total number (n) of antibodies tested per individual is shown on top of each bar. (B) The bar graph shows the distribution of nAbs with different neutralization potencies. nAbs were classified as weakly neutralizing (> 500 ng/mL; pale orange), medium neutralizing (100 – 500 ng/mL; orange), highly neutralizing (10 – 100 ng/mL; dark orange) and extremely neutralizing (1 – 10 ng/mL; dark red). The total number (n) of antibodies tested per individual is shown on top of each bar. " width="100%" height="100%">

Journal: Cell

Article Title: Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

doi: 10.1016/j.cell.2021.02.035

Figure Lengend Snippet: Characterization and distribution of SARS-CoV-2 S protein-specific nAbs, related to Figure 2 (A) The bar graph shows the distribution of nAbs binding to different S-protein domains. In dark red, light blue and gray are shown antibodies binding to the S1-domain, S2-domain and S-protein trimer respectively. The total number (n) of antibodies tested per individual is shown on top of each bar. (B) The bar graph shows the distribution of nAbs with different neutralization potencies. nAbs were classified as weakly neutralizing (> 500 ng/mL; pale orange), medium neutralizing (100 – 500 ng/mL; orange), highly neutralizing (10 – 100 ng/mL; dark orange) and extremely neutralizing (1 – 10 ng/mL; dark red). The total number (n) of antibodies tested per individual is shown on top of each bar.

Article Snippet: SARS Coronavirus Spike Glycoprotein (S2) , The Native Antigen Company , Cat#REC31807.

Techniques: Binding Assay, Neutralization

Functional characterization of potent SARS-CoV-2 S protein-specific nAbs (A–C) Graphs show binding curves to the S protein in its trimeric conformation, S1 domain, and S2 domain. Mean ± SD of technical triplicates are shown. Dashed lines represent the threshold of positivity. (D–F) Neutralization curves for selected antibodies were shown as percentage of viral neutralization against the authentic SARS-CoV-2 wild type (D), D614G variant (E), and the emerging variant B.1.1.7 (F). Data are representative of technical triplicates. A neutralizing COVID-19 convalescent plasma and an unrelated plasma were used as positive and negative control, respectively. (G–I) Neutralization potency of 14 selected antibodies against the authentic SARS-CoV-2 wild type (G), D614G variant (H), and the emerging variant B.1.1.7 (I). Dashed lines show different ranges of neutralization potency (500, 100, and 10 ng/mL). In all graphs, selected antibodies are shown in dark red, pink, gray, and light blue based on their ability to recognize the SARS-CoV-2 S1 RBD, S1 domain, S protein trimer only, and S2 domain, respectively.

Journal: Cell

Article Title: Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

doi: 10.1016/j.cell.2021.02.035

Figure Lengend Snippet: Functional characterization of potent SARS-CoV-2 S protein-specific nAbs (A–C) Graphs show binding curves to the S protein in its trimeric conformation, S1 domain, and S2 domain. Mean ± SD of technical triplicates are shown. Dashed lines represent the threshold of positivity. (D–F) Neutralization curves for selected antibodies were shown as percentage of viral neutralization against the authentic SARS-CoV-2 wild type (D), D614G variant (E), and the emerging variant B.1.1.7 (F). Data are representative of technical triplicates. A neutralizing COVID-19 convalescent plasma and an unrelated plasma were used as positive and negative control, respectively. (G–I) Neutralization potency of 14 selected antibodies against the authentic SARS-CoV-2 wild type (G), D614G variant (H), and the emerging variant B.1.1.7 (I). Dashed lines show different ranges of neutralization potency (500, 100, and 10 ng/mL). In all graphs, selected antibodies are shown in dark red, pink, gray, and light blue based on their ability to recognize the SARS-CoV-2 S1 RBD, S1 domain, S protein trimer only, and S2 domain, respectively.

Article Snippet: SARS Coronavirus Spike Glycoprotein (S2) , The Native Antigen Company , Cat#REC31807.

Techniques: Functional Assay, Binding Assay, Neutralization, Variant Assay, Negative Control

Neutralization activity of selected nAbs against SARS-CoV-2, SARS-CoV, and MERS-CoV pseudotypes, related to <xref ref-type=Figure 3 (A–D) Graphs show the neutralizing activities of 14 selected nAbs with different SARS-CoV-2 S-protein binding profiles against SARS-CoV-2, SARS-CoV-2 D614G, SARS-CoV and MERS-CoV pseudotypes respectively. Dashed lines represent the threshold of positivity. Mean ± SD of technical duplicates are shown. In all graphs selected antibodies are shown in dark red, pink, gray and light blue based on their ability to recognize the SARS-CoV-2 S1-RBD, S1-domain, S-protein trimer only and S2-domain respectively. " width="100%" height="100%">

Journal: Cell

Article Title: Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

doi: 10.1016/j.cell.2021.02.035

Figure Lengend Snippet: Neutralization activity of selected nAbs against SARS-CoV-2, SARS-CoV, and MERS-CoV pseudotypes, related to Figure 3 (A–D) Graphs show the neutralizing activities of 14 selected nAbs with different SARS-CoV-2 S-protein binding profiles against SARS-CoV-2, SARS-CoV-2 D614G, SARS-CoV and MERS-CoV pseudotypes respectively. Dashed lines represent the threshold of positivity. Mean ± SD of technical duplicates are shown. In all graphs selected antibodies are shown in dark red, pink, gray and light blue based on their ability to recognize the SARS-CoV-2 S1-RBD, S1-domain, S-protein trimer only and S2-domain respectively.

Article Snippet: SARS Coronavirus Spike Glycoprotein (S2) , The Native Antigen Company , Cat#REC31807.

Techniques: Neutralization, Activity Assay, Protein Binding

Characterization of Fc-engineered candidate nAbs, related to <xref ref-type=Figure 7 (A) the graph shows binding curves of J08, I14 and F05 MUT and WT to the FcγR2A. (B and C) graphs show binding curves of J08, I14 and F05 MUT and WT to the FcRn at pH 6.2 (B) and 7.4 (C). (D and E) Graphs show the ADNP and ADNK induced by J08, I14 and F05 MUT and WT versions; all the experiments were run as technical duplicates. In every experiment a control antibody (CR3022) and an unrelated protein were used as positive and negative control respectively. (F–H) Graphs show binding curves to the S-protein in its trimeric conformation, S1-domain and S2-domain. Mean of technical triplicates are shown. (I–K) Neutralization curves against the authentic SARS-CoV-2 wild type, the D614G variant and the B.1.1.7 emerging variant for J08-MUT, I14-MUT and F05-MUT shown in blue, green and red respectively. Data are representative of technical triplicates. " width="100%" height="100%">

Journal: Cell

Article Title: Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

doi: 10.1016/j.cell.2021.02.035

Figure Lengend Snippet: Characterization of Fc-engineered candidate nAbs, related to Figure 7 (A) the graph shows binding curves of J08, I14 and F05 MUT and WT to the FcγR2A. (B and C) graphs show binding curves of J08, I14 and F05 MUT and WT to the FcRn at pH 6.2 (B) and 7.4 (C). (D and E) Graphs show the ADNP and ADNK induced by J08, I14 and F05 MUT and WT versions; all the experiments were run as technical duplicates. In every experiment a control antibody (CR3022) and an unrelated protein were used as positive and negative control respectively. (F–H) Graphs show binding curves to the S-protein in its trimeric conformation, S1-domain and S2-domain. Mean of technical triplicates are shown. (I–K) Neutralization curves against the authentic SARS-CoV-2 wild type, the D614G variant and the B.1.1.7 emerging variant for J08-MUT, I14-MUT and F05-MUT shown in blue, green and red respectively. Data are representative of technical triplicates.

Article Snippet: SARS Coronavirus Spike Glycoprotein (S2) , The Native Antigen Company , Cat#REC31807.

Techniques: Binding Assay, Negative Control, Neutralization, Variant Assay

Journal: Cell

Article Title: Extremely potent human monoclonal antibodies from COVID-19 convalescent patients

doi: 10.1016/j.cell.2021.02.035

Figure Lengend Snippet:

Article Snippet: SARS Coronavirus Spike Glycoprotein (S2) , The Native Antigen Company , Cat#REC31807.

Techniques: Virus, Recombinant, Expressing, Transfection, Enzyme-linked Immunosorbent Assay, Antibody Labeling, Bicinchoninic Acid Protein Assay, Clone Assay, Random Hexamer Labeling, Plasmid Preparation, Mutagenesis, Luciferase, Software